<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066503</url>
  </required_header>
  <id_info>
    <org_study_id>260279</org_study_id>
    <nct_id>NCT05066503</nct_id>
  </id_info>
  <brief_title>Nutritional Therapy for Delirium in Elderly Hospitalized Subjects</brief_title>
  <official_title>Nutritional Therapy for Delirium in Elderly Hospitalized Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have developed a proprietary blend of amino acids that they think will help&#xD;
      to prevent or reduce the severity of delirium in older people who are hospitalized for&#xD;
      certain infections. In this study, up to 45 people will be enrolled. 15 will be asked to&#xD;
      drink this blend twice a day for up to 1 week, and 15 will drink a placebo (sugar water) for&#xD;
      the same time period. The other 15 subjects will be non-delirious control subjects who do not&#xD;
      consume any study products.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CAM-S (Confusion Assessment Method-Short) score from baseline to day 3 or up to day 7.</measure>
    <time_frame>As determined over an up to 7-day intervention duration.</time_frame>
    <description>CAM-S is a tool to determine and quantify delirium. Subjects in the non-control arms will undergo this test twice each day. The score ranges from 0-7, with lower numbers being better (little to no signs of delirium).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Subacute Delirium</condition>
  <arm_group>
    <arm_group_label>Delirious subjects receiving active study product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will ingest an oral amino-acid containing nutritional supplement twice daily for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delirious subjects receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will ingest a flavored, sweetened, inactive drink twice daily for up to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-delirious control subjects who receive no intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects receive no intervention and are observed for 2-3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>260279 active study product</intervention_name>
    <description>The active study product (20g per serving) contains 13.6g of amino acids and natural flavors, citric acid, malic acid, and stevia for flavoring.</description>
    <arm_group_label>Delirious subjects receiving active study product</arm_group_label>
    <other_name>there is not a non-proprietary name for this supplement.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>260279 placebo</intervention_name>
    <description>A drink made of flavored, sweetened water.</description>
    <arm_group_label>Delirious subjects receiving placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Delirious cohort&#xD;
&#xD;
          1. Aged 65 years and older.&#xD;
&#xD;
          2. Documented presence of either delirium, acute confusion, or altered mental status in&#xD;
             medical record.&#xD;
&#xD;
          3. Currently hospitalized with a diagnosis of one of the following:&#xD;
&#xD;
               1. sepsis/septicemia&#xD;
&#xD;
               2. Pneumonia&#xD;
&#xD;
               3. Urinary tract infection&#xD;
&#xD;
               4. Clostridium-difficile infection&#xD;
&#xD;
        Inclusion Criteria: NON-Delirious cohort&#xD;
&#xD;
          1. Aged 65 years and older.&#xD;
&#xD;
          2. Current diagnosis of one of the following:&#xD;
&#xD;
               1. sepsis/septicemia&#xD;
&#xD;
               2. Pneumonia&#xD;
&#xD;
               3. Urinary tract infection&#xD;
&#xD;
               4. Clostridium-difficile infection&#xD;
&#xD;
        Exclusion Criteria: all subjects&#xD;
&#xD;
          1. Chronic kidney disease (eGFR &lt;30).&#xD;
&#xD;
          2. History of Parkinson's disease.&#xD;
&#xD;
          3. History of a major psychiatric illness.&#xD;
&#xD;
          4. Delirium etiology of drug overdose or alcohol withdrawal.&#xD;
&#xD;
          5. Current hyponatremia.&#xD;
&#xD;
          6. Currently on sedative/hypnotic medications and not expected to stop.&#xD;
&#xD;
          7. Major surgery within the past two weeks.&#xD;
&#xD;
          8. Known or suspected Covid-19 positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gohar Azhar, M.D.</last_name>
    <phone>5015265821</phone>
    <email>azhargohar@uams.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAMS Center on Aging</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Schutzler, RN</last_name>
      <phone>501-526-5734</phone>
      <email>seschutzler@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Jeanne Wei, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Onna Lau, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bader Alkharisi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anil Anandam, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sakiru Isa, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regina Gibson, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taylor Gregory, P.A.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Coker</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

